First response

60% reduction in severe outcomes.

Refractory PPH

6 delays

01

First response · E-MOTIVE ↓

Once PPH is detected, the MOTIVE bundle is triggered all at once.

The bundle for every recognised PPH: the trial, the system behind it, the cost, and the real-world evidence.

02

Refractory PPH and the six delays ↓

When the first response treatment fails:  Escalate.

There are six critical delays: a view of where time is lost.

The E-MOTIVE trial

All drugs and techniques listed here have long been part of established guidelines. E-MOTIVE focused on the importance of timing and combination: This was examined across 80 secondary hospitals in Kenya, Nigeria, South Africa, and Tanzania, involving 210,132 women having vaginal births. [1]

Why the E-MOTIVE bundle

E-MOTIVE was designed and evaluated as an integrated intervention for the early detection and treatment of postpartum haemorrhage. The “E” component centres on early detection through routine use of a calibrated blood-collection drape, allowing blood loss to be measured objectively and predefined treatment thresholds to be recognised promptly.

Once PPH is identified, the MOTIVE treatment bundle is initiated without delay: uterine Massage, Oxytocic drugs, Tranexamic acid, IntraVenous fluids, Vaginal/genital tract Examination, and escalation of care where required.

When the trigger fires, five components arrive at once: massage, oxytocics, tranexamic acid, intravenous fluids and examination. Below, the E-MOTIVE trial results: detection rose from 51.1 to 93.1 percent, bundle delivery from 19.4 to 91.2 percent, and severe outcomes fell from 4.3 to 1.6 percent.

E-MOTIVE

▪ Observations (cumulative blood loss volume, blood flow, uterine tone) every 15 minutes documented on the blood loss monitoring chart

▪ Blood pressure and pulse carried out at least once in the 1st hour postpartum and documented on the blood loss monitoring chart

E · Early detection of postpartum haemorrhage

E

Early detection of postpartum haemorrhage

▼

Trigger criteria

1) Clinical judgment
2) Blood loss 300 mL or more plus one abnormal observation
3) Blood loss 500 mL or more

Massage of uterus

M

Massage
of uterus

Oxytocic drug

O

Oxytocic
drug

Tranexamic acid

T

Tranexamic
acid

IV fluids

IV

IV fluids

Examination of the genital tract

E

Examination of
the genital tract
+ Escalation

▼

Treatment for
Refractory PPH

Massage until uterus has contracted or for one minute

10 IU IV Oxytocin slow injection (>2 mins) or diluted in 200–500 mL crystalloid over 10 minutes plus a maintenance dose of 20 IU IV oxytocin diluted in 1000 mL saline over 4 hours (± misoprostol)

Tranexamic acid 1 g IV injection or diluted in 200 mL crystalloid over 10 minutes

IV fluids should be given if clinically indicated and may require a 2nd IV access

Ensure bladder is empty, evacuate clots, check for genital tract tears with an internal Examination and check placenta for completeness

Implementation strategies (ACTT)

Audit newsletters: sharing with all staff monthly detection and bundle use rates along with numbers of PPH, severe PPH, blood transfusion, laparotomy and death from PPH; feedback given at monthly departmental meetings.

Champions: Midwife and doctor to oversee change, troubleshoot, give feedback on audit newsletters, connect with other champions through chats, meetings and websites for sharing knowledge and lessons learnt.

Trolley and/or carry case: including all medicines and devices required for the treatment of PPH; restocked after every use; and a stocking checklist completed at the start of every shift.

Training: on-site, simulation-based, and peer-assisted training of 90 minutes facilitated by the use of provider guides, flipcharts and job aids displayed in labour wards.

Does E-MOTIVE apply effectively in real-world settings?

E-MOTIVE’s effectiveness has remained consistent outside trial settings. In Pakistan, a before-and-after study at eight hospitals assessed E-MOTIVE under routine conditions. The outcome of severe PPH, laparotomy for bleeding, or death from bleeding fell from 20 cases per 1,000 births with usual care to fewer than 1 per 1,000 with the E-MOTIVE intervention, a 97% reduction in risk. PPH detection improved from half of all cases to every case, and first-response bundle use from 4 in 10 women to all women. [4].

The overall evidence includes one large trial across four African countries, an implementation study in Pakistan.

The cost of E-MOTIVE

An economic evaluation conducted alongside the trial showed that the E-MOTIVE intervention was cost-effective [3]. The adjusted cost difference was US$0.30 per patient (95% CI −2.31 to 2.78), with an estimated US$11.83 per case of severe PPH prevented, and US$113.91 per disability-adjusted life-year (DALY) averted.

When the willingness-to-pay threshold surpasses roughly US$1,500 per DALY averted, the probability of cost-effectiveness exceeds 80% [3]. Since costs and thresholds vary between countries, ministries should combine this evidence with local budget-impact analysis.

The economic analysis dispels the assumption that better outcomes necessarily entail higher costs beyond what the system can afford.

In practice · Same woman. Same blood loss. Different outcomes.

USUAL CARE

THE E-MOTIVE PATHWAY

Clock with rising pulse line and question mark

Estimated blood loss

Blood loss is estimated visually and recorded as normal.

Calibrated drape with check mark

Objective blood loss measurement

The drape reads 520 mL at thirty minutes. Based on this measurement:

Clock with rising pulse line and question mark

Delayed diagnosis

An hour on, the woman is pale and tachycardic; the blood loss is re-estimated at “maybe 600”.

Calibrated drape with check mark

PPH is diagnosed

The first-response bundle is initiated within fifteen minutes of diagnosis [6].

Medicine vial and tablet

Response begins

A uterotonic is given.

Hands cupping a uterus

MOTIVE bundle

Uterine massage begins, oxytocics, tranexamic acid, IV fluids are administered,

Medicine vial with clock

After review

Tranexamic acid is considered at the next review.

IV infusion bag

Examination and escalation

and the examination reveals a small vaginal tear, which is repaired in the room [5].

Medicine vial with clock

By the time the diagnosis is confirmed, the woman is experiencing severe PPH, and the response is escalation to theatre.

IV infusion bag

Bleeding is stopped or escalation begins.

When the first response treatment fails

Examination and Escalation

Refractory postpartum haemorrhage refers to bleeding that does not respond to the first response treatment. Life-threatening postpartum haemorrhage can lead to shock, collapse or organ failure [2]. Recognisable warning signs include drowsiness, confusion, breathlessness, low urine output, blood loss of 1,500 mL or more, pulse above 110, systolic pressure below 90 mmHg, and a shock index of 1.7 or higher [2].

Once one or more of these signs appear, surgical and haematological interventions are necessary: tamponade, compression sutures, major vessel ligation, embolisation (where an interventional radiologist is available), and hysterectomy as a last resort. These interventions should be supported by transfusions and correction of coagulopathy, which can develop early and rapidly [2] [7].

A Race Against Time · Escalation and refractory PPH

The six delays between diagnosis and survival.

Postpartum haemorrhage is a rapidly evolving trajectory, not a singular event. This progression to complications or death can occur within minutes [2]. These six critical delays must be addressed [2].

Where healthcare systems can fail

A facility might diagnose postpartum haemorrhage accurately, but delays in treating it (for example, low-quality oxytocin) can still lead to a woman’s death. Additional factors include the unavailability of blood transfusion services or slow referral processes.

South Africa’s triennial confidential enquiries into maternal deaths [9] revealed that 70% of obstetric haemorrhage deaths involved avoidable healthcare factors, such as insufficient blood supply, transport delays between facilities, and overburdened services causing management delays [2].

TO REVIEW
Measuring intervals such as the time from birth to PPH to diagnosis, from diagnosis to first response treatment, and from request for blood to transfusion pinpoints where delays occur within the treatment pathway [8]. Each delay has a specific solution.

 

In practice · Two versions of the same hour
In practice · An illustrative scenario

An illustrative scenario based on maternal death review findings.

Escalation · An illustrative scenario

Same blood loss. A different response.

500 mL estimated. 860 mL actual. Treatment starts; bleeding continues.

WHERE THE SYSTEM LOSES HER

WHERE THE SYSTEM CATCHES HER

Clipboard with question mark and clock

No agreed red flags

No automatic escalation; senior opinion is 40 minutes away.

Checklist with flag and monitor

Automatic escalation

Red flags displayed; the call is automatic at 1,000 mL with a rising shock index.

Falling blood drops

Bleeding continues

Blood loss increases while the team waits for senior review.

Uterus with balloon tamponade

Tamponade buys time

A temporary measure while definitive care is arranged.

Blood bag with clock

Blood ordered late

Blood is requested only once she is already in shock.

Blood bag with check mark

Blood already prepared

Cross-matched in advance under the facility’s agreed protocol.

Ambulance with clock

Two hours to referral

Transport to the referral hospital takes two hours.

Operating theatre with oxygen cylinder

Ready for theatre care

She reaches theatre warm, oxygenated and correctable.

Make escalation a system response.

Illustrative scenario. The 1,000 mL escalation point shown is a local rule in this example.

03

← Previous · PPH Diagnosis. Objective measurement and the new definition

05

Next → Implementation. Guidelines, roadmap and the moment

References